DOCSLIB.ORG

COVID-19 Vaccination Reporting Updated As of 8A.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccination Reporting Updated As of 8A.M Mississippi State Department of Health COVID-19 Vaccination Reporting Updated as of 8a.m. September 28, 2021 (Data are Provisional) Vaccine providers administering COVID-19 vaccine are required to report the doses administered to the Mississippi Immunization Information Exchange (MIIX), the statewide immunization registry, within 24 hours after administration Total Reported Vaccinations by Mississippi Providers* Vaccine Doses Administered by Race* Total Doses Administered 2,796,003 Race Received at Least One Dose** Fully Vaccinated*** Third or Booster Dose Vaccinations % of Total Doses Administered People Receiving at Least One Dose** 1,499,404 White 779,851 693,537 32,471 1,470,115 57% People Fully Vaccinated*** 1,310,134 Black 533,061 467,515 12,838 992,634 38% People Receiving Booster Dose of Pfizer or 3rd Dose of Pfizer or Asian 24,139 22,187 540 46,190 2% 47,986 Moderna for Immunocompromising Conditions AIAN**** 3,883 3,248 87 7,103 0% *Includes Federal Agency Doses Administered (Bureau of Prisons, Veterans Health, Indian Health Services, Dept. of Defense) Pacific Islander 1,625 1,386 39 2,998 0% **One dose of Pfizer/Moderna or one dose of Johnson and Johnson vaccine Multi-racial 237 196 3 422 0% ***Two doses of Pfizer/Moderna or one dose of Johnson and Johnson vaccine Other 44,097 37,907 873 79,924 3% Vaccine Administration Over the Prior Week 9/19-9/26 (By Age Group)* Totals 1,386,893 1,225,976 46,851 2,599,386 100% Age Group At Least One Dose Fully Vaccinated Third or Booster Dose *Those with unknown race are excluded 12-15 1,122 2,240 12 **One dose of Pfizer/Moderna or one dose of Johnson and Johnson vaccine 16-17 463 1,012 8 ***Second dose of Pfizer/Moderna or one dose of Johnson and Johnson vaccine 18-24 1,999 3,615 61 ****American Indian and Alaskan Native 25-39 3,840 7,020 206 Vaccine Doses Administered by Ethnicity* 40-49 2,193 4,463 890 Ethnicity Received at Least One Dose** Fully Vaccinated*** Third or Booster Dose Vaccinations % of Total Doses Administered 50-64 2,649 5,485 1,284 Not Hispanic 1,275,895 1,131,308 44,678 2,397,007 97% 65-74 907 1,649 2,228 Hispanic 39,427 32,124 361 69,914 3% 75+ 497 842 1,700 Totals 1,315,322 1,163,432 45,039 2,466,921 100% Total 13,670 26,326 6,389 *Those with unknown ethnicity are excluded *Those with unknown ages are excluded **One dose of Pfizer/Moderna or one dose of Johnson and Johnson vaccine Total Vaccine Doses Administered by Facility ***Second dose of Pfizer/Moderna or one dose of Johnson and Johnson vaccine Facility First Dose Second Dose Third or Booster Dose Total Vaccine Doses Administered by Facility Over the Prior Week (9/19/2021-9/26/2021) Hospital 156,180 142,738 4,381 Facility First Dose Second Dose Third or Booster Dose Total (% of total doses administered) Pharmacies 506,081 392,883 17,747 Hospital 775 1,236 302 2,313 (5%) MSDH Vaccination Efforts 406,581 343,489 6,594 Pharmacies 8,134 15,945 1,952 26,031 (57%) Clinics 372,993 323,200 19,264 MSDH Vaccination Efforts 282 502 1,085 1,869 (4%) Clinics 13,859 8,340 2,510 15,518 (32%) Federal Agency COVID-19 Vaccine Administration Facility First Dose Second Dose Third or Booster Dose MS & US Fully Vaccinated Rates by Age Groups Bureau of Prisons 2,868 2,607 7 Age Groups United States Mississippi Veterans Health 24,020 20,753 186 % of total Pop 55% 44% Indian Health Service 4,818 3,891 2 % ≥12 Years of age 65% 50% Dept. of Defense 25,863 15,188 1 % ≥18 Years of age 67% 52% Totals 57,569 42,439 196 % ≥65 Years of age 83% 75% Percentage of Total Pop. Receiving at least One Dose by County** Percentage of Total Pop. Fully Vaccinated by County*** **One dose of Pfizer/Moderna or one dose of Janssen (Johnson and Johnson) vaccine ***Second dose of Pfizer/Moderna or one dose of Janssen (Johnson and Johnson) vaccine Age Groups Reported First, Second and Third COVID-19 Vaccine Doses Administered by Age Group (% of Age Group Fully Vaccinated )** People Receiving One or More Doses People Fully Vaccinated*** Third or Booster Doses Administered 450,000 389,373 400,000 352,890 (62%) 350,000 300,000 250,269 237,243 250,000 223,865 (77%) 204,236 (35%) 206,432 200,000 178,684 (50%) 151,846 143,643 (73%) 150,000 114,362 89,956 (32%) 100,000 59,955 47,402 (29%) Number Number Vaccinations of 50,000 31,211 26,007 (33%) 16,182 97 86 684 2,664 3,559 11,660 13,054 0 12-15 16-17 18-24 25-39 Age Group 40-49 50-64 65-74 75+ **Those with unknown ages are excluded ***Two doses of Pfizer/Moderna or one dose of Johnson and Johnson vaccine Weekly Overall Totals Reported COVID-19 Vaccine Doses Administered by Week*** (Includes First, Second and Third Doses) 160,000 140,000 132,042 131,887 128,841 127,763 122,672 114,492 120,000 106,691 100,000 91,686 91,237 85,034 86,051 75,549 80,000 74,383 71,135 62,615 61,822 56,812 58,150 56,332 55,876 55,638 52,951 51,697 60,000 46,440 38,491 40,245 38,716 40,000 32,578 32,540 33,502 28,487 24,374 25,669 25,599 27,171 22,438 19,956 20,008 20,000 9,365 10,217 4,356 5,504 Number Vaccinations of Number 0 Dec. 19, Dec. 26, Jan. 2, Jan. 9, Jan. 16, Jan. 23, Jan. 30, Feb. 6, Feb. 13, Feb. 20, Feb. 27, Mar. 6, Mar. 13, Mar. 20, Mar. 27, Apr. 3, Apr. 10, Apr. 17, Apr. 24, May. 1, May. 8, May. 15, May. 22, May. 29, June. 5, June. 12, June. 19, June. 26, July. 3, July. 10, July. 17, July. 24, July. 31, Aug. 7, Aug. 14, Aug. 21, Aug. 28, Sept. 4, Sept. 11, Sept. 18, Sept. 25, Oct. 2, 2020 2020 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 Week Ending ***Those with unknown week of vaccine administration are excluded Weekly Dose Totals Reported COVID-19 Vaccine Doses Administered by Week*** (Includes First, Second and Third Doses) Moderna Pfizer Johnson and Johnson 160000 140000 6021 4527 4047 120000 12517 8335 100000 70443 3438 1564 71235 867 51204 73843 72002 624 80000 53131 60435 953 43463 991 53859 52348 598 329 381 60000 988 245 41861 1055 % of Total Pop. Fully Vaccinated Total Doses Administered58171 24308 33799 53022 27986 1179 1574 695 50019 235 40000 30964 43975 40105 37420 68574 7794 1035 25%1039 557 36993 33562 9333 59051 13653 61617 57264 28244 805 902 711 495 652 16762 47344 50471 51714 45722 17755 22586 27898 24724 20000 38921 36102 37325 16824 15855 19364 32361 30451 32521 7355 1546720%16706 14235 13702 13348 1607127013 37 Number Vaccinations of 3579 24259 20845 24076 17141 20163 21903 17716 18531 17890 5012 14568 14331 10628 8842 11652 14970 16856 13757 0 43884 4632 7096 2244 8102 18%7924 7492 5759 6008 7250 4651 14674000 Dec. 19, Dec. 26, Jan. 2, Jan. 9, Jan. 16, Jan. 23, Jan. 30, Feb. 6, Feb. 13, Feb. 20, Feb. 27, Mar. 6, Mar. 13, Mar. 20, Mar. 27, Apr. 3, Apr. 10, Apr. 17, Apr. 24, May. 1, May. 8, May. 15, May. 22, May. 29, June. 5, June. 12, June. 19, June. 26, July. 3, July. 10, July. 17, July. 24, July. 31, Aug. 7, Aug. 14, Aug. 21, Aug. 28, Sept. 4, Sept. 11, Sept. 18, Sept. 25, Oct. 2, 2020 2020 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 202147492021 2021 2021 2021 26%2021 2021 2021 2021 2021 2021 2021 2021 2021 2021102042021 2021 2021 2021 2021 2021 2021 Week Ending1609 19% 3448 ***Those with unknown week of vaccine administration are excluded Vaccine Doses Administered by County of Residence (Updated as of 8am 9/28/2021)* County of Residence People Receiving at least One Dose** % of Total Pop. Receving at least One Dose People Fully Vaccinated*** % of Total Pop. Fully Vaccinated Total Doses Administered Adams 14743 48% 12486 41% 27295 Alcorn 13409 36% 11614 31% 25133 Amite 4288 35% 3802 31% 7831 Attala 9530 52% 8292 46% 17919 Benton 3486 42% 3094 37% 6480 Bolivar 17498 57% 15651 51% 32769 Calhoun 6238 43% 5132 36% 10830 Carroll 3960 40% 3570 36% 7573 Chickasaw 8138 48% 7260 42% 15086 Choctaw 2794 34% 2497 30% 5138 Claiborne 4715 52% 4118 46% 8702 Clarke 7858 51% 6829 44% 14456 Clay 8573 44% 7755 40% 15584 Coahoma 10564 48% 9272 42% 19372 Copiah 14560 52% 12998 46% 27263 Covington 9085 49% 7954 43% 17071 Desoto 80108 43% 70467 38% 150462 Forrest 30159 40% 26481 35% 56696 Franklin 3537 46% 3156 41% 6580 George 9466 39% 8236 34% 17282 Greene 4824 36% 4306 32% 9008 Grenada 10634 51% 9558 46% 20223 Hancock 16204 34% 13942 29% 29609 Harrison 90671 44% 78528 38% 167859 Hinds 125093 54% 112869 49% 238651 Holmes 9708 57% 8437 50% 17833 Humphreys 4632 57% 3895 48% 8411 Issaquena 462 35% 406 31% 883 Itawamba 8028 34% 7262 31% 14969 Jackson 60815 42% 53055 37% 114767 Jasper 8020 49% 6955 42% 14883 Jefferson 4646 66% 4010 57% 8503 Jefferson Davis 4679 42% 4173 38% 8839 Jones 28543 42% 24662 36% 54373 Kemper 4215 43% 3800 39% 7949 Lafayette 28725 53% 26460 49% 55644 Lamar 36355 57% 32684 52% 69687 Lauderdale 35775 48% 31898 43% 66739 Lawrence 6718 53% 5983 48% 13411 Leake 9880 43% 8715 38% 18402 Lee 36192 42% 32909 39% 68474 Leflore 17078 61% 15190 54% 32453 Lincoln 12895 38% 11382 33% 24261 Lowndes 26286 45% 23807 41% 49656 Madison 64835 61% 59458 56% 124734 Marion 10510 43% 9232 38% 19389 Marshall 15190 43% 13193 37% 27749 Monroe 17367 49% 15747 45% 32434 Montgomery 5251 54% 4752 49% 10030 Neshoba 8917 31% 7862 27% 16711 Newton 10199 49% 9108 43% 18830 Noxubee 5558 53% 5037 48% 9965 Oktibbeha 24999 50% 22848 46% 47421 Panola 15035 44% 13134 38% 27977 Pearl River 20385 37% 17498 32% 36833 Perry 4330 36% 3762 31% 7988 Pike 18325 47% 16017 41% 33645 Pontotoc 13213 41% 11859 37% 24776 Prentiss 10545 42% 9200 37% 19534 Quitman 3395 50% 2909 43% 6198 Rankin 77208 50% 70145 45% 147912 Scott 13717 49% 12069 43%
Load more

Recommended publications
  • Mississippi-Alabama Sea Grant Consortium 2018-21 Strategic Plan Table of Contents Strategic Planning Process
    Mississippi-Alabama Sea Grant Consortium 2018-21 Strategic Plan Table of Contents Strategic Planning Process .............................................................................................................. 1 External and Internal Input ......................................................................................................... 1 Vision ............................................................................................................................................... 3 Mission ............................................................................................................................................ 3 Core Values ..................................................................................................................................... 3 Organizational Excellence ............................................................................................................... 3 Partnerships .................................................................................................................................... 4 Shared Positions While Leveraging Partnerships ........................................................................ 4 Gulf Sea Grant Programs ............................................................................................................. 4 State and Local Agencies ............................................................................................................. 5 Federal Agencies ........................................................................................................................
    [Show full text]
  • Vaccination Certificate Information Version: 21 July 2021
    معلومات عن شهادة التطعيم، بالعربية 中文疫苗接种凭证信息 Informations sur le certificat de vaccination en FRANÇAIS Информация о сертификате вакцинации на РУССКОМ ЯЗЫКЕ Información sobre el Certificado de Vacunación en ESPAÑOL UN SYSTEM-WIDE COVID-19 VACCINATION PROGRAMME VACCINATION CERTIFICATE INFORMATION VERSION: 21 JULY 2021 ABOUT THE UN SYSTEM-WIDE COVID-19 VACCINATION PROGRAMME The UN is committed to ensuring the protection of its personnel. Tasked by the Secretary-General, the Department of Operational Support (DOS) is leading a coordinated, UN-system-wide effort to ensure the availability of vaccine to UN personnel, their dependents and implementing partners. The roll-out of the UN System-wide COVID-19 Vaccination Programme (the “Programme”) for UN personnel will provide a significant boost to the ability of personnel to stay and deliver on the Organization's mandates, to support beneficiaries in the communities they serve, and to contribute to our on-going work to recover better together from the pandemic. Information about the Programme is available at: https://www.un.org/en/coronavirus/vaccination ABOUT THE VACCINATION CERTIFICATE Upon administration of the requisite vaccine dosage, a certificate of vaccination is generated through the Programme’s registration platform (the “Platform”). The certificate generated by the Platform uses a standardized format, similar to the one used by the WHO in its “International Certificate of Vaccination or Prophylaxis” (Yellow) vaccination booklet. Note: This certificate may not dispense with travel restrictions put in place by the country(ies) of destination. As the nature of the pandemic continues to rapidly evolve, it is highly advisable to check the latest travel regulations.
    [Show full text]
  • Global Dynamics of a Vaccination Model for Infectious Diseases with Asymptomatic Carriers
    MATHEMATICAL BIOSCIENCES doi:10.3934/mbe.2016019 AND ENGINEERING Volume 13, Number 4, August 2016 pp. 813{840 GLOBAL DYNAMICS OF A VACCINATION MODEL FOR INFECTIOUS DISEASES WITH ASYMPTOMATIC CARRIERS Martin Luther Mann Manyombe1;2 and Joseph Mbang1;2 Department of Mathematics, Faculty of Science University of Yaounde 1, P.O. Box 812 Yaounde, Cameroon 1;2;3; Jean Lubuma and Berge Tsanou ∗ Department of Mathematics and Applied Mathematics University of Pretoria, Pretoria 0002, South Africa (Communicated by Abba Gumel) Abstract. In this paper, an epidemic model is investigated for infectious dis- eases that can be transmitted through both the infectious individuals and the asymptomatic carriers (i.e., infected individuals who are contagious but do not show any disease symptoms). We propose a dose-structured vaccination model with multiple transmission pathways. Based on the range of the explic- itly computed basic reproduction number, we prove the global stability of the disease-free when this threshold number is less or equal to the unity. Moreover, whenever it is greater than one, the existence of the unique endemic equilibrium is shown and its global stability is established for the case where the changes of displaying the disease symptoms are independent of the vulnerable classes. Further, the model is shown to exhibit a transcritical bifurcation with the unit basic reproduction number being the bifurcation parameter. The impacts of the asymptomatic carriers and the effectiveness of vaccination on the disease transmission are discussed through through the local and the global sensitivity analyses of the basic reproduction number. Finally, a case study of hepatitis B virus disease (HBV) is considered, with the numerical simulations presented to support the analytical results.
    [Show full text]
  • The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given
    Hepatitis B Vaccine Protect Yourself and Those You Love What is Hepatitis B? Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV), which attacks liver cells and can lead to liver failure, cirrhosis (scarring), or liver cancer later in life. The virus is transmitted through direct contact with infected blood and bodily fluids, and from an infected woman to her newborn at birth. Is there a safe vaccine for hepatitis B? YES! The good news is that there is a safe and effective vaccine for hepatitis B. The vaccine is a series, typically given as three shots over a six-month period that will provide a lifetime of protection. You cannot get hepatitis B from the vaccine – there is no human blood or live virus in the vaccine. The hepatitis B vaccine is the most widely used vaccine in the world, with over 1 billion doses given. The hepatitis B vaccine is the first "anti-cancer" vaccine because it can help prevent liver cancer! Who should be vaccinated against hepatitis B? The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend the hepatitis B vaccine for all newborns and children up to 18 years of age, and all high-risk adults. All infants should receive the first dose of the vaccine in the delivery room or in the first 24 hours of life, preferably within 12 hours. (CDC recommends the first dose within 12 hours vs. the WHO recommendation of 24 hours.) The HBV vaccine is recommended to anyone who is at high risk of infection.
    [Show full text]
  • Mississippi Population Fact Sheet
    Mississippi Fact Sheet Population Growth, Millennials, Brain Drain, and the Economy A Report to the Governor Dr. Mimmo Parisi Professor of Demography Department of Sociology Mississippi State University January 19, 2018 2017 Population Growth by the Numbers Population growth depends on multiple factors that includes Population Growth = (Births-Deaths) + (Net Domestic Migration + Net numbers of births and deaths, net International Migration) domestic migration, and net international migration. How each factor contributes to population Population Growth = (37,373 – 30,875) + (-9,885 + 2,087) growth must be seen in relation to the others. All factors must be Population Growth = 6,498 – 7,798 examined together to provide an accurate picture of any population Population Growth = -1,300 estimate. Also, all factors must be seen in the context of national trends to fully understand the magnitude of their impact on a given state. The estimates presented in the following slides provide detailed information on each factor that contributes to population growth, along with information on millennials, brain drain, and overall state economic indicators. Source: U.S. Census Bureau, Population Division, 2017. https://www2.census.gov/programs-surveys/popest/datasets/2010-2017/national/totals/ 3 Mississippi Population, 2000-2017 The estimates for 2016 and 2017 indicate that the population declined by 1,300. This decline is within the estimation margin of error and it will be revised next year, therefore this number needs to be interpreted cautiously. It also means that there has been no substantive decline in total population. The only conclusion one can draw from these estimates is that the Mississippi total 3,000,000 2,988,578 population has remained fairly stable.
    [Show full text]
  • Mississippi Kite (Ictinia Mississippiensis)
    Mississippi Kite (Ictinia mississippiensis) NMPIF level: Species Conservation Concern, Level 2 (SC2) NMPIF assessment score: 15 NM stewardship responsibility: Low National PIF status: No special status New Mexico BCRs: 16, 18, 35 Primary breeding habitat(s): Urban (southeast plains) Other habitats used: Agricultural, Middle Elevation Riparian Summary of Concern Mississippi Kite is a migratory raptor that has successfully colonized urban habitats (parks, golf courses, residential neighborhoods) in the western portion of its breeding range over the last several decades. Little is known about species ecology outside of the breeding season and, despite stable or increasing populations at the periphery of its range, it remains vulnerable due to its small population size. Associated Species Cooper’s Hawk, Ring-necked Pheasant, Mourning Dove, American Robin Distribution Mississippi Kite is erratically distributed across portions of the east and southeast, the southern Great Plains, and the southwest, west to central Arizona and south to northwest Chihuahua. It is most abundant in areas of the Gulf Coast, and in the Texas and Oklahoma panhandles. The species is a long- distance migrant, wintering in Argentina, Paraguay, and perhaps other locations in South America. In New Mexico, Mississippi Kite is most common in cites and towns of the southeast plains. It is also present in the Middle Rio Grande valley north to Corrales, and the Pecos River Valley north to Fort Sumner and possibly Puerto de Luna (Parker 1999, Parmeter et al. 2002). Ecology and Habitat Requirements Mississippi Kite occupies different habitats in different parts of its range, including mature hardwood forests in the southeast, rural woodlands in mixed and shortgrass prairie in the Great Plains, and mixed riparian woodlands in the southwest.
    [Show full text]
  • State Abbreviations
    State Abbreviations Postal Abbreviations for States/Territories On July 1, 1963, the Post Office Department introduced the five-digit ZIP Code. At the time, 10/1963– 1831 1874 1943 6/1963 present most addressing equipment could accommodate only 23 characters (including spaces) in the Alabama Al. Ala. Ala. ALA AL Alaska -- Alaska Alaska ALSK AK bottom line of the address. To make room for Arizona -- Ariz. Ariz. ARIZ AZ the ZIP Code, state names needed to be Arkansas Ar. T. Ark. Ark. ARK AR abbreviated. The Department provided an initial California -- Cal. Calif. CALIF CA list of abbreviations in June 1963, but many had Colorado -- Colo. Colo. COL CO three or four letters, which was still too long. In Connecticut Ct. Conn. Conn. CONN CT Delaware De. Del. Del. DEL DE October 1963, the Department settled on the District of D. C. D. C. D. C. DC DC current two-letter abbreviations. Since that time, Columbia only one change has been made: in 1969, at the Florida Fl. T. Fla. Fla. FLA FL request of the Canadian postal administration, Georgia Ga. Ga. Ga. GA GA Hawaii -- -- Hawaii HAW HI the abbreviation for Nebraska, originally NB, Idaho -- Idaho Idaho IDA ID was changed to NE, to avoid confusion with Illinois Il. Ill. Ill. ILL IL New Brunswick in Canada. Indiana Ia. Ind. Ind. IND IN Iowa -- Iowa Iowa IOWA IA Kansas -- Kans. Kans. KANS KS A list of state abbreviations since 1831 is Kentucky Ky. Ky. Ky. KY KY provided at right. A more complete list of current Louisiana La. La.
    [Show full text]
  • Soils of Mississippi County, Arkansas
    Soils of Mississippi County, Arkansas J.M. McKimmey, B. Dixon, H.D. Scott, and C.M. Scarlat ARKANSAS AGRICULTURAL EXPERIMENT STATION Division of Agriculture University of Arkansas November 2002 Research Report 970 Additional printed copies of this publication can be obtained free of charge from Communication Services, 110 Agriculture Building, University of Arkansas, Fayetteville, AR 72701. This publication is available on the Internet at: http://www.uark.edu/depts/agripub/Publications/ Additional information on soils in Arkansas is available at soils.uark.edu Technical editing and cover design by Cam Romund Arkansas Agricultural Experiment Station, University of Arkansas Division of Agriculture, Fayetteville. Milo J. Shult, Vice President for Agriculture and Director; Gregory J. Weidemann, Dean, Dale Bumpers College of Agricultural, Food and Life Sciences and Associate Vice President for Agriculture–Research, University of Arkansas Division of Agriculture. CPB777QX5. The University of Arkansas Division of Agriculture follows a nondiscriminatory policy in programs and employment. ISSN:1539-5944 CODEN:AKABA7 Soils of Mississippi County, Arkansas J.M. McKimmey, Research Specialist B. Dixon, Research Specialist H.D. Scott, University Professor C.M. Scarlat, Research Specialist All authors are associated with the Department of Crop, Soil, and Environmental Sciences University of Arkansas Arkansas Agricultural Experiment Station Fayetteville, Arkansas 72701 CONTENTS INTRODUCTION ...........................................................................................................................
    [Show full text]
  • Vaccine Hesitancy
    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
    [Show full text]
  • AAMC Standardized Immunization Form
    AAMC Standardized Immunization Form Middle Last Name: First Name: Initial: DOB: Street Address: Medical School: City: Cell Phone: State: Primary Email: ZIP Code: AAMC ID: MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option. Copy Note: a 3rd dose of MMR vaccine may be advised during regional outbreaks of measles or mumps if original MMR vaccination was received in childhood. Attached Option1 Vaccine Date MMR Dose #1 MMR -2 doses of MMR vaccine MMR Dose #2 Option 2 Vaccine or Test Date Measles Vaccine Dose #1 Serology Results Measles Qualitative -2 doses of vaccine or Measles Vaccine Dose #2 Titer Results: Positive Negative positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Mumps Vaccine Dose #1 Serology Results Mumps Qualitative -2 doses of vaccine or Mumps Vaccine Dose #2 Titer Results: Positive Negative positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Serology Results Rubella Qualitative Positive Negative -1 dose of vaccine or Rubella Vaccine Titer Results: positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Tetanus-diphtheria-pertussis – 1 dose of adult Tdap; if last Tdap is more than 10 years old, provide date of last Td or Tdap booster Tdap Vaccine (Adacel, Boostrix, etc) Td Vaccine or Tdap Vaccine booster (if more than 10 years since last Tdap) Varicella (Chicken Pox) - 2 doses of varicella vaccine or positive serology Varicella Vaccine #1 Serology Results Qualitative Varicella Vaccine #2 Titer Results: Positive Negative Serologic Immunity (IgG antibody titer) Quantitative Titer Results: _____ IU/ml Influenza Vaccine --1 dose annually each fall Date Flu Vaccine © 2020 AAMC.
    [Show full text]
  • Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC)
    AAMC Standardized Immunization Form 2020 Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC) 1. What are the hepatitis B vaccines licensed for use in the United States? Three single-antigen vaccines and two combination vaccines are currently licensed in the United States. Single-antigen hepatitis B vaccines: • ENGERIX-B® • RECOMBIVAX HB® • HEPLISAV-B™ Combination vaccines: • PEDIARIX®: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years. • TWINRIX®: Combined Hepatitis A and hepatitis B vaccine. Recommended for people aged ≥18 years who are at increased risk for both HAV and HBV infections. 2. What are the recommended schedules for hepatitis B vaccination? The vaccination schedule most often used for children and adults is three doses given at 0, 1, and 6 months. Alternate schedules have been approved for certain vaccines and/or populations. A new formulation, Heplisav-B (HepB-CpG), is approved to be given as two doses one month apart. 3. If there is an interruption between doses of hepatitis B vaccine, does the vaccine series need to be restarted? No. The series does not need to be restarted but the following should be considered: • If the vaccine series was interrupted after the first dose, the second dose should be administered as soon as possible. • The second and third doses should be separated by an interval of at least 8 weeks. • If only the third dose is delayed, it should be administered as soon as possible. 4. Is it harmful to administer an extra dose of hepatitis B vaccine or to repeat the entire vaccine series if documentation of the vaccination history is unavailable or the serology test is negative? No, administering extra doses of single-antigen hepatitis B vaccine is not harmful.
    [Show full text]
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
    [Show full text]